RU2016136630A - Способы гликоконъюгирования и композиции - Google Patents
Способы гликоконъюгирования и композиции Download PDFInfo
- Publication number
- RU2016136630A RU2016136630A RU2016136630A RU2016136630A RU2016136630A RU 2016136630 A RU2016136630 A RU 2016136630A RU 2016136630 A RU2016136630 A RU 2016136630A RU 2016136630 A RU2016136630 A RU 2016136630A RU 2016136630 A RU2016136630 A RU 2016136630A
- Authority
- RU
- Russia
- Prior art keywords
- glycoconjugate
- kda
- polysaccharide
- immunogenic composition
- capsular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 6
- 150000004676 glycans Chemical class 0.000 claims 12
- 229920001282 polysaccharide Polymers 0.000 claims 12
- 239000005017 polysaccharide Substances 0.000 claims 12
- 230000002163 immunogen Effects 0.000 claims 5
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Claims (16)
1. Гликоконъюгат, содержащий бактериальный капсульный полисахарид, конъюгированный с белком-носителем через еТЕС спейсер, где полисахарид ковалентно связан с еТЕС спейсером через карбаматную связь, и белок-носитель ковалентно связан с еТЕС спейсером через амидную связь.
2. Гликоконъюгат по п. 1, где капсульный полисахарид имеет происхождение из S. pneumoniae и выбран из группы, состоящей из капсульных полисахаридов Pn-серотипов 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F и 33F.
3. Гликоконъюгат по п. 2, где капсульный полисахарид представляет собой капсульный полисахарид Pn-серотипа 10A, 11A, 22F или 33F.
4. Гликоконъюгат по п. 1, где капсульный полисахарид имеет происхождение из N. meningitidis.
5. Гликоконъюгат по п. 1, где полисахарид имеет молекулярную массу в диапазоне от 10 кДа до 2000 кДа, от 50 кДа до 2000 кДа, от 50 кДа до 20000 кДа или от 500 кДа до 10000 кДа.
6. Гликоконъюгат по п. 1, где полисахарид имеет степень О-ацетилирования в диапазоне 75-100%.
7. Гликоконъюгат по п. 1, где белок-носитель представляет собой CRM197.
8. Гликоконъюгат по п. 7, где CRM197 содержит 2-20 или 4-16 остатков лизина, ковалентно связанных с полисахаридом через еТЕС спейсер.
9. Гликоконъюгат по п. 1, где соотношение сахарид : (белок-носитель) (масс./масс.) составляет от 0,2 до 4 или от 0,4 до 1,7.
10. Гликоконъюгат по п. 7, где на каждые 25, 15, 10 или 4 повторяющихся сахаридных единиц сахарида встречается по меньшей мере одна связь между CRM197 и сахаридом.
11. Гликоконъюгат по любому из п.п. 1-10, имеющий распределение молекул по размерам (Kd) не менее 35% при не более 0,3.
12. Иммуногенная композиция, содержащая гликоконъюгат по любому из пп. 1-11 и фармацевтически приемлемый эксципиент, носитель или разбавитель.
13. Иммуногенная композиция по п. 12, дополнительно содержащая дополнительный антиген.
14. Иммуногенная композиция по п. 13, где дополнительный антиген содержит гликоконъюгат капсульного полисахарида, выбранного из группы, состоящей из капсульных полисахаридов Pn-серотипов 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F и 33F.
15. Иммуногенная композиция по любому из п.п. 12-14, дополнительно содержащая адъювант.
16. Иммуногенная композиция по п. 15, где адъювант представляет собой адъювант на основе алюминия, выбранный из группы, состоящей из фосфата алюминия, сульфата алюминия и гидроксида алюминия.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 | |
| US61/684.043 | 2012-08-16 | ||
| US61/684,043 | 2012-08-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015103017A Division RU2645071C2 (ru) | 2012-08-16 | 2013-08-12 | Способы гликоконъюгирования и композиции |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016136630A true RU2016136630A (ru) | 2018-12-11 |
| RU2016136630A3 RU2016136630A3 (ru) | 2019-12-30 |
| RU2724840C2 RU2724840C2 (ru) | 2020-06-25 |
Family
ID=49385307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015103017A RU2645071C2 (ru) | 2012-08-16 | 2013-08-12 | Способы гликоконъюгирования и композиции |
| RU2016136630A RU2724840C2 (ru) | 2012-08-16 | 2013-08-12 | Способы гликоконъюгирования и композиции |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015103017A RU2645071C2 (ru) | 2012-08-16 | 2013-08-12 | Способы гликоконъюгирования и композиции |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9517274B2 (ru) |
| EP (2) | EP2885007B1 (ru) |
| JP (1) | JP6291495B2 (ru) |
| KR (1) | KR101742406B1 (ru) |
| CN (1) | CN104661684B (ru) |
| AR (1) | AR092368A1 (ru) |
| AU (1) | AU2013303826B2 (ru) |
| BR (1) | BR112015003227B1 (ru) |
| CA (1) | CA2881420C (ru) |
| DK (2) | DK3421051T3 (ru) |
| ES (2) | ES2800479T3 (ru) |
| FI (1) | FIC20220032I1 (ru) |
| FR (1) | FR22C1037I2 (ru) |
| HU (3) | HUE049531T2 (ru) |
| IL (1) | IL237066B (ru) |
| IN (1) | IN2015DN00694A (ru) |
| LU (1) | LUC00273I2 (ru) |
| MX (1) | MX363511B (ru) |
| MY (1) | MY167579A (ru) |
| NL (1) | NL301188I2 (ru) |
| NO (1) | NO2022034I1 (ru) |
| NZ (1) | NZ704490A (ru) |
| PE (1) | PE20150464A1 (ru) |
| PH (1) | PH12015500243B1 (ru) |
| PL (2) | PL2885007T3 (ru) |
| PT (2) | PT3421051T (ru) |
| RU (2) | RU2645071C2 (ru) |
| SA (1) | SA515360035B1 (ru) |
| SG (1) | SG11201500566XA (ru) |
| SI (2) | SI3421051T1 (ru) |
| TW (1) | TWI480049B (ru) |
| WO (1) | WO2014027302A1 (ru) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2881420C (en) | 2012-08-16 | 2016-11-15 | Pfizer Inc. | Glycoconjugation processes and compositions |
| NZ721943A (en) * | 2014-01-21 | 2022-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| RU2710393C2 (ru) * | 2014-01-21 | 2019-12-26 | Пфайзер Инк. | Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20160324949A1 (en) * | 2014-01-21 | 2016-11-10 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| EP3443983B1 (en) * | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
| SMT202100231T1 (it) | 2014-03-13 | 2021-05-07 | Univ Basel | Ligandi di carboidrato che si legano ad anticorpi igm contro glicoproteina associata a mielina |
| IL252915B2 (en) | 2015-01-15 | 2024-04-01 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
| KR102045663B1 (ko) * | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| PE20180460A1 (es) * | 2015-06-08 | 2018-03-06 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos |
| TWI756893B (zh) | 2015-07-21 | 2022-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| AU2016323377B2 (en) | 2015-09-16 | 2021-04-15 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| CN109862908B (zh) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| JP7001686B2 (ja) | 2016-08-05 | 2022-02-04 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物 |
| LT3506935T (lt) | 2016-09-02 | 2024-04-25 | Sanofi Pasteur, Inc. | Vakcina nuo neisseria meningitidis |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| AU2018208844B2 (en) | 2017-01-20 | 2021-02-25 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| KR20240018698A (ko) * | 2017-06-10 | 2024-02-13 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
| US11491216B2 (en) | 2017-09-07 | 2022-11-08 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| BR112020004410A8 (pt) * | 2017-09-07 | 2023-01-31 | Merck Sharp & Dohme | Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora |
| KR102812816B1 (ko) | 2018-02-05 | 2025-05-27 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| IL276230B2 (en) | 2018-02-05 | 2024-01-01 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| RU2020131305A (ru) * | 2018-03-23 | 2022-04-26 | Коранекс Кэпитал | Прецизионные гликоконъюгаты в качестве терапевтических инструментов |
| US11951162B2 (en) | 2018-04-18 | 2024-04-09 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| EP4107192A1 (en) | 2020-02-21 | 2022-12-28 | Pfizer Inc. | Purification of saccharides |
| BR112022014555A2 (pt) | 2020-02-23 | 2022-09-20 | Pfizer | Composições de escherichia coli e métodos das mesmas. |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| EP4213870A1 (en) | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| CA3199094A1 (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3199610A1 (en) | 2020-10-27 | 2022-05-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20230097160A (ko) | 2020-11-04 | 2023-06-30 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| KR20230175284A (ko) | 2021-05-28 | 2023-12-29 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| EP4626405A1 (en) | 2022-12-01 | 2025-10-08 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| CN121038808A (zh) | 2023-03-30 | 2025-11-28 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2293739A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| PT1117435E (pt) | 1998-09-30 | 2008-02-21 | Us Gov Univ Health Sciences | Holotoxina da cólera mutante como adjuvante |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| DK1355673T3 (da) * | 2001-01-23 | 2012-09-17 | Sanofi Pasteur Inc | Multivalent meningococvaccine bestående af et polysaccharid/proteinkonjugat |
| CN1977971A (zh) | 2001-06-07 | 2007-06-13 | 惠氏控股有限公司 | 作为佐剂的霍乱全毒素的突变体形式 |
| BR0210216A (pt) | 2001-06-07 | 2004-06-08 | Wyeth Corp | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| US6995001B2 (en) * | 2002-10-03 | 2006-02-07 | Wyeth Holdings Corporation | Processing for preparing monoprotected diols from symmetric diols |
| NZ561879A (en) * | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| PL1735321T3 (pl) * | 2004-04-14 | 2009-04-30 | Wyeth Corp | Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| DK2384765T3 (en) * | 2005-12-22 | 2017-01-09 | Glaxosmithkline Biologicals Sa | Vaccine against Streptococcus pneumoniae. |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| CN101394867A (zh) * | 2006-03-07 | 2009-03-25 | 惠氏公司 | 大环内酯类免疫抑制剂的水溶性聚乙二醇结合物的制备方法 |
| WO2007127668A2 (en) | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| US20100189740A1 (en) * | 2007-06-20 | 2010-07-29 | Francis Michon | Modified polysaccharides for conjugate vaccines |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| EP3461496B1 (en) * | 2009-06-22 | 2023-08-23 | Wyeth LLC | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| CA2766614C (en) * | 2009-07-03 | 2018-06-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| CA2781120C (en) * | 2009-11-24 | 2015-01-27 | Jianxin Guo | Lyophilization methods, compositions, and kits |
| CN103391714A (zh) * | 2010-12-10 | 2013-11-13 | 默沙东公司 | 减轻搅动引起的免疫原性组合物聚集的新制剂 |
| MX358840B (es) * | 2011-09-07 | 2018-09-05 | Prolynx Llc | Hidrogeles con reticulación biodegradable. |
| CA2881420C (en) * | 2012-08-16 | 2016-11-15 | Pfizer Inc. | Glycoconjugation processes and compositions |
| NZ721943A (en) | 2014-01-21 | 2022-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3443983B1 (en) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en not_active Ceased
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US12447203B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016136630A (ru) | Способы гликоконъюгирования и композиции | |
| RU2015100140A (ru) | Поливалентная композиция, содержащая конъюгаты пневмококковый полисахарид-белок | |
| IL276229B2 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| JP2020533438A5 (ru) | ||
| RU2019112411A (ru) | Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены и их применение | |
| TN2012000377A1 (en) | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition | |
| TW200719911A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| MX2013006539A (es) | Formulaciones novedosas que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas. | |
| RU2015121771A (ru) | Мультивалентная композиция на основе конъюгатов пневмококковый полисахарид-белок | |
| JP2020533439A5 (ru) | ||
| JP2019526621A5 (ru) | ||
| Danieli et al. | Synthesis of Staphylococcus aureus type 5 capsular polysaccharide repeating unit using novel L-FucNAc and D-FucNAc synthons and immunochemical evaluation | |
| PH12015501269A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| WO2011151760A3 (en) | Streptococcus pneumoniae vaccine formulations | |
| MX2009006547A (es) | Composicion conjugada polisacarido-proteina neumococica multivalente. | |
| EA200801935A1 (ru) | Конъюгатные вакцины | |
| MX2009006548A (es) | Composicion conjugada polisacarido-proteina neumococica multivalente. | |
| WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
| JP2019526620A5 (ru) | ||
| EA201990126A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция | |
| FI2968427T3 (fi) | Konjugaatti sienisoluseinämän polysakkarideihin kohdentuvien vasta-aineiden indusoimiseksi | |
| JPWO2020058963A5 (ru) | ||
| TH1901001172A (th) | องค์ประกอบของคอนจูเกตของมัลติวาเลนท์นิวโมคอคคัสแคปซูลาร์โพลีแซคคาไรด์-โปรตีนตัวพา และการใช้ของมัน | |
| RU2020112308A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| EA201990131A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция |